Latest News

Category: Events

See all

Telix to Present at Jefferies Healthcare Conference

Events, News,

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors,...

Read more

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Events, News,

Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.  Institutional investors, analysts and company guests are cordially...

Read more

Telix at ANZSNM 2023

Events, News,

Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May. We...

Read more

Telix to Showcase Innovation in Urology at AUA Annual Meeting, including New ZIRCON Phase III Data in Very Small Renal Masses

Events, News,

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be...

Read more

Telix-Grand Pharma Investor Webcast

Events, News,

Telix is pleased to provide a video recording of the joint webcast with Telix’s exclusive partner for the Greater China market, Grand Pharma held on 20 April 2023. ...

Read more

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Events, News,

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga...

Read more

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU

Events, News,

Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...

Read more

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Events, News,

Telix today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held...

Read more

Webcast of Investor Briefing: ASCO GU ZIRCON Phase III Results Presentation

Events, News,

Telix is pleased to provide a webcast recording of A/Prof Brian Shuch and Dr Colin Hayward, Telix Group Chief Medical Officer. The briefing provided an opportunity for investors to hear...

Read more

Telix at ASCO GU 2023

Events,

ASCO GU (February 16-18, 2023), the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present results of the Phase III ZIRCON...

Read more